CoChat

Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors

Open access

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

Older adults are among the most vulnerable to adverse cognitive effects of psychotropic medications and, therefore, the personalization of psychotropic treatment based on adverse drug reactions in this demographic is of great importance. We examined changes on neuropsychological tests of attention attributable to selective serotonin reuptake inhibitor (SSRI) treatment in anxious older adults. We also examined whether variation in serotonin receptor genes was associated with reduced attentional performance with SSRIs. We examined change from pre- to post-treatment in two attention measures - digit span and coding - in 133 adults aged ≥60 yr with generalized anxiety disorder in a 12-wk trial of escitalopram vs. placebo. We also examined attentional change in relation to genetic variability in four central serotonin receptors: the serotonin transporter and serotonin 1A, 2A and 1B receptors. Digit span scores were significantly lowered in patients receiving escitalopram relative to placebo, indicating reduced attentional performance attributable to the SSRI. Individuals with high-transcription variants in the receptors 5-HTR2A rs6311 and 5-HTR1B rs11568817 had greater reductions in attention with SSRI treatment compared to placebo. We conclude that SSRIs reduce attention in older adults, particularly in those with high-expression genetic variants at the serotonin 2A and 1B receptors. Analysing neuropsychological changes with SSRIs in relation to genetic variation in the serotonin system may be a useful strategy for detecting subgroups of older adults who are more susceptible to side-effects of SSRIs. These results, if confirmed, could lead to the personalization of SSRI use to reduce adverse neurocognitive effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s1461145712000351

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Research works printed but not linked: 3

  1. 1992, NONMEM Users Guides
  2. 1996, Structured Clinical Interview for DSM-IV Axis I Disorders (SCID)
  3. 1998, Repeatable Battery for the Assessment of Neuropsychological Status Manual

Cited by

See all 23

Metadata

Authors
Lenze, E. J., Dixon, D., Nowotny, P., Lotrich, F. E., Doré, P. M., Pollock, B. G., Hinrichs, A. L., & Butters, M. A.
Affiliations
  • Washington University in St. Louis (US)
  • University of Pittsburgh (US)
  • Centre for Addiction and Mental Health (CA)
Corresponding author
Lenze, Eric J.
Venue
International Journal of Neuropsychopharmacology
Published
2012-04-17
Volume
16
Issue
2
Pages
279-288
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2131845222
Cited by
23
References
56
Citations by year
2026: 1 · 2025: 1 · 2023: 2 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2017: 5 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 3
FWCI
0.92
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
Funders
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • National Institutes of Health (UL1TR000005)
  • National Institute of Mental Health (R01MH072947, K23MH074012, R01MH070547)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
escitalopram, selective serotonin reuptake inhibitors, attention, generalized anxiety disorder, older adults, serotonin receptor gene, 5-HT2A receptor, 5-HT1B receptor, 5-HT1A receptor, serotonin transporter, genetic polymorphism, digit span, adverse drug reactions, individualized drug therapy, cognitive side effects
MeSH terms
Aged, Aged, 80 and over, Anxiety, Attention, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Surveys and Questionnaires, Retrospective Studies, Time Factors, Citalopram, Selective Serotonin Reuptake Inhibitors, Statistics, Nonparametric, Polymorphism, Single Nucleotide, Receptor, Serotonin, 5-HT1B, Receptor, Serotonin, 5-HT2A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors. https://app.cochat.ai/papers/10.1017/s1461145712000351
The paper
Lenze, E. J., Dixon, D., Nowotny, P., Lotrich, F. E., Doré, P. M., Pollock, B. G., Hinrichs, A. L., & Butters, M. A. (2013). Escitalopram reduces attentional performance in anxious older adults with high-expression genetic variants at serotonin 2A and 1B receptors. International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145712000351

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.